Candel Therapeutics(CADL)
Focus: Candel Therapeutics is a public-stage oncology-focused biotechnology company specializing in oncolytic viral immunotherapies for solid tumors including lung, pancreatic, prostate, and brain cancers. The company operates as a clinical-stage biotech with a diversified pipeline across multiple tumor types.
Profile data last refreshed 3h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
0
About Candel Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow Candel Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Candel Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
4/9 — Basic
Company HealthStrong
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
AdV-tk
Malignant GliomaClinical Trials (1)
NCT00634231A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors
Phase 1Help build intelligence for Candel Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.